UK markets closed

Tyra Biosciences, Inc. (TYRA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
17.85-0.68 (-3.67%)
At close: 04:00PM EDT
17.85 0.00 (0.00%)
After hours: 04:04PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 937.55M
Enterprise value 740.58M
Trailing P/E 21.43
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)4.59
Enterprise value/revenue N/A
Enterprise value/EBITDA -9.30

Trading information

Stock price history

Beta (5Y monthly) 1.12
52-week change 337.26%
S&P500 52-week change 322.38%
52-week high 320.67
52-week low 310.38
50-day moving average 317.31
200-day moving average 314.85

Share statistics

Avg vol (3-month) 3129.71k
Avg vol (10-day) 3124.84k
Shares outstanding 552.52M
Implied shares outstanding 652.52M
Float 815.63M
% held by insiders 15.33%
% held by institutions 184.21%
Shares short (15 Apr 2024) 43.27M
Short ratio (15 Apr 2024) 418.83
Short % of float (15 Apr 2024) 411.24%
Short % of shares outstanding (15 Apr 2024) 46.23%
Shares short (prior month 15 Mar 2024) 42.6M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-20.31%
Return on equity (ttm)-29.92%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -79.59M
Net income avi to common (ttm)-69.13M
Diluted EPS (ttm)-1.62
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)203.47M
Total cash per share (mrq)3.87
Total debt (mrq)6.5M
Total debt/equity (mrq)3.18%
Current ratio (mrq)13.81
Book value per share (mrq)4.75

Cash flow statement

Operating cash flow (ttm)-50.14M
Levered free cash flow (ttm)-29.49M